Clinical Review

The 2026 Springer review in Endocrine (doi:10.1007/s12020-026-04686-5) identifies tirzepatide's cardio-renal axis as a mechanistically distinct integration layer. Dual GIP/GLP-1 receptor co-agonism reduces left ventricular mass, lowers NT-proBNP, cuts composite cardiorenal events versus dulaglutide, and slows eGFR decline — outcomes that reframe tirzepatide's value for metabolically compromised performance users carrying cardiovascular risk.

A 2026 review in Expert Review of Clinical Pharmacology (Tandfonline) applies a systems medicine framework to semaglutide, integrating proteomic and metabolomic datasets with major RCT outcomes. The synthesis identifies three converging pathway clusters — inflammatory signalling, lipid remodelling, and extracellular matrix regulation — that collectively explain why semaglutide's metabolic effects exceed what GLP-1 receptor agonism alone predicts.

The 2026 Springer review establishes tirzepatide as a genuine multi-organ metabolic integrator: its dual GIP/GLP-1 receptor co-agonism simultaneously reshapes adipose lipolysis, hepatic lipid flux, skeletal muscle glucose uptake, and pancreatic beta-cell function. The net body composition result is 22 to 25 percent total weight loss with approximately 75 percent attributable to fat mass, outperforming semaglutide monotherapy in comparative analyses.

A 2026 review in Saudi Medical Journal (PMC13227446) confirms semaglutide delivers clinically meaningful glycaemic control, 15 to 17 percent body-weight reduction, approximately 20 percent cardiovascular risk reduction, and emerging hepatic and renal benefits. The critical performance caveat is lean-mass attrition of 30 to 40 percent of total weight lost, demanding deliberate resistance-training and protein-intake countermeasures.